An interventional study of Dexmedetomidine and Placebo in Postoperative Delirium, Gastrointestinal Surgery and Aged, sponsored by Hanoi Medical University. Not yet recruiting at 1 site in Vietnam. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by Hanoi Medical University · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 83 studies testing dexmedetomidine in Emergence Delirium — 31 open to participants now, 32 under way, 2 of them phase 3. Dexmedetomidine · Emergence Delirium.
Among the 83 studies testing dexmedetomidine in Emergence Delirium, this one is the 3rd largest by planned enrollment, is one of 16 that started in 2026, is one of 27 with no phase, reaches primary completion later than 30 of the 31 other live ones, and was the 83rd registered.
753 studies on the registry are indexed under Emergence Delirium; 261 are open to participants now.
Browse Emergence Delirium studies →31 of the 83 studies testing dexmedetomidine in Emergence Delirium are open now, in 10 countries. Recruiting first, the newest first:
Pakistan Institute of Medical Sciences · Sites in Pakistan
Ages 2–12 · Healthy volunteers
Boston Children's Hospital · Sites in United States
Ages 1–12
Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital · Sites in Turkey
Ages 2–10
Bach Mai Hospital · Sites in Vietnam
Ages 18–65
Kasr El Aini Hospital · Sites in Egypt
Ages 2–6
By country, each count listing its studies:
Dexmedetomidine: first FDA approval 1999 (PRECEDEX), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 141 Emergence Delirium studies recruiting now, 78 (55%) set no upper age limit and 43 (30%) stop at 75 or younger; 33 take children under 18; 24 take healthy volunteers.
This study: 60 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
83 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 11 · Phase 3 13 · Phase 4 31
First in 2006; this study’s year is marked. 16 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 630 is above the median of 120 across 467 interventional studies indexed under Emergence Delirium.
Median enrollment 100 across the 83 interventional studies. Of the 38 that completed or were terminated, 10 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 83 have an industry lead sponsor. The 10 most frequent:
Hanoi Medical University is the lead sponsor of 56 studies on the registry; 18 are open to participants now.
Hanoi Medical University has 1 study filed under Emergence Delirium — fewer than ten, so there is no comparison to draw.
13 of the studies testing dexmedetomidine in Emergence Delirium that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07538284Phase 3Sixth Affiliated Hospital, Sun Yat-sen UniversityMInimizing Delirium With Nasal Dexmedetomidine-InducEd Sleep (MIDDIES) | 2026-12-31 |
| NCT07810556Phase 3Assiut UniversityIntrathecal Dexmedetomidine and Postoperative Delirium in Elderly Hip Fracture Surgery | 2027-10 |
| NCT07519863Ain Shams UniversityThe Effect of Dormicum-Ketamine Versus Dexmedetomidine on Emergence Delirium During Deep Sedation in Paediatric Burn Patients | 2026-11 |
| NCT07799311Pakistan Institute of Medical SciencesComparing the Efficacy of Propofol and Dexmedetomidine in Prevention of Emergence Agitation After Sevoflurane Anesthesia in Children | 2026-11-28 |
| NCT07601698Sohag UniversityDexmedetomidine vs Propofol-lidocaine Mixture in Preventing the Post Operative Emergence Agitation Following Sevoflurane Anasthesia | 2026-11-30 |
Add all 13 to your calendar (.ics) → With an account.
Among the 83 studies testing dexmedetomidine in Emergence Delirium, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Postoperative delirium (POD) is a common and serious complication in older adults after major gastrointestinal surgery and is associated with longer hospital stay, long-term cognitive decline and higher mortality. Dexmedetomidine, a highly selective alpha-2 adrenergic agonist with sedative, anti-inflammatory and opioid-sparing effects, may reduce POD, but evidence in older patients undergoing gastrointestinal surgery remains inconsistent, and tools to identify which patients are at highest risk are lacking.
The goal of this randomized, double-blind, placebo-controlled trial is to learn whether intraoperative and early postoperative dexmedetomidine prevents POD in patients aged 60 years or older undergoing elective gastrointestinal surgery under general anesthesia, and to develop a risk prediction nomogram for POD in this population. The main questions it aims to answer are:
Researchers will also examine how dexmedetomidine changes postoperative inflammatory and stress markers (IL-6, cortisol, CRP, NLR, SII) and their association with POD, and whether the benefit of dexmedetomidine differs across baseline-risk strata.
Participants will be randomly assigned to dexmedetomidine or placebo (0.9% saline). The blinded infusion starts 15 minutes before induction of anesthesia (dexmedetomidine 0.5 mcg/kg over 15 minutes, then 0.5 mcg/kg/h until 2 hours after surgery, or the same volume and rate of saline). Delirium will be assessed three times daily with the 3D-CAM (or CAM-ICU for patients who cannot be interviewed) from the end of surgery until postoperative day 5 or hospital discharge.
Design: Single-center, randomized, double-blind, placebo-controlled, parallel-group (1:1) superiority trial with an embedded prediction-model development study, conducted at Hanoi Medical University Hospital, Hanoi, Vietnam. The protocol follows SPIRIT 2025; results will be reported according to CONSORT 2025 and prediction models according to TRIPOD+AI 2024. Approved by the Hanoi Medical University Institutional Ethical Review Board (certificate 5315/GCN-DHYHN, HMUIRB3022, 2 November 2026).
Primary outcomes: (1) Incidence of POD through postoperative day 5 - tested two-sided at alpha 0.05. (2) Predictive performance of the POD nomograms (optimism-corrected C-statistic, calibration slope and intercept, Brier score) - reported as point estimates with 95% CI, without hypothesis testing; therefore no alpha splitting is applied. All other analyses are secondary and interpreted as exploratory.
Randomization and allocation concealment: An independent investigator not involved in recruitment or assessment generates the allocation sequence in R using permuted blocks of randomly varying size. Sequentially numbered, opaque, sealed envelopes (1-630) are opened in the operating room by an independent nurse who prepares the study drug.
Blinding: Participants, anesthesiologists, surgeons, ward nurses, delirium assessors, laboratory staff and data analysts are blinded. Dexmedetomidine (200 mcg in 50 mL, 4 mcg/mL) and placebo (50 mL 0.9% saline) are prepared in identical 50-mL syringes with identical labels, volume and infusion rate. Emergency unblinding is permitted only when knowledge of allocation would change clinical management.
Anesthesia protocol: No benzodiazepine premedication; anticholinergics minimized. Induction with fentanyl 2 mcg/kg, titrated propofol to PSi 25-50, rocuronium 0.8 mg/kg; maintenance with sevoflurane titrated to PSi 25-50; TOF-guided neuromuscular blockade; protective ventilation; non-invasive blood pressure every 3 minutes. Postoperative analgesia per routine practice, with regional techniques according to surgery; total opioid use is recorded.
Delirium assessment: Trained, blinded assessors (inter-rater kappa >= 0.8) perform the 3D-CAM three times daily (07:00-09:00, 12:00-14:00, 18:00-20:00) from the end of surgery through postoperative day 5 or hospital discharge. Sedation is assessed with RASS before each assessment; patients with RASS -3 to -1 who cannot be interviewed are assessed with CAM-ICU. Severity is graded by 3D-CAM-S. 10% of assessments are double-rated for quality control.
Laboratory substudy: The first 60 randomized patients (30 per group) undergo IL-6 (baseline, 2 h and 24 h after surgery) and 08:00 cortisol (baseline, postoperative days 1 and 2) measurements. CRP and complete blood count (for NLR and SII) are measured in all patients before surgery and at 24 h and 48 h after surgery. The substudy is analyzed after the 60 patients complete follow-up; this pre-specified secondary analysis excludes delirium outcomes and is not used for any decision on stopping, sample size or protocol modification.
Sample size: Primary outcome 1: assuming POD incidence of 25% with placebo and 10% with dexmedetomidine (Lee et al., 2018), alpha 0.05 and power 80%, 224 patients (112 per group, including 10% attrition) are required. Primary outcome 2: following Riley et al. (2020) (outcome prevalence 17.5%, up to 6 candidate parameters, Cox-Snell R-squared 0.0907), at least 566 patients are required; allowing 10% attrition, 630 patients (315 per group) will be enrolled. The sample size is therefore driven by primary outcome 2 and gives more than 80% power for primary outcome 1.
Statistical analysis: The primary analysis population is the modified intention-to-treat (mITT) population (all randomized patients who started study-drug infusion), with per-protocol sensitivity analysis; safety is analyzed by treatment received. Primary outcome 1 is compared with chi-square/Fisher's exact test and reported as RR, absolute risk difference and NNT with 95% CI; adjusted RR by robust Poisson regression (age, MMSE, high-risk surgery and covariates with \|SMD\| > 0.1). Biomarker trajectories are analyzed with linear mixed-effects models. Missing data are handled by multiple imputation (MICE, 20 datasets) with complete-case and best/worst-case sensitivity analyses. Pre-specified subgroups: age \< 75 vs >= 75, high-risk surgery, open vs laparoscopic, MMSE \< 24 vs >= 24, CFS \<= 4 vs >= 5. No interim efficacy analysis is planned.
Prediction models: Pre-specified logistic models (no data-driven variable selection, maximum 6 parameters, uniform bootstrap shrinkage): Model A (preoperative: age, MMSE, Clinical Frailty Scale, serum albumin, high-risk surgery, treatment group) and Model B (end of surgery: age, MMSE, CFS, surgical duration, cumulative time with MAP \< 65 mmHg, treatment group; plus a sensitivity version updating the Model A linear predictor). Internal validation by 1,000 bootstrap replicates; temporal validation when >= 30 events are available. Secondary: model comparison, decision curve analysis over thresholds of 5-40%, and treatment-effect heterogeneity by quartiles of baseline risk from Model A following the PATH statement (pre-specified, exploratory). Nomograms are research products and will not guide treatment of trial participants.
Safety monitoring: An independent monitoring group reviews safety after 25%, 50% and 75% of enrollment or every 6 months, whichever comes first. Serious adverse events are reported to the ethics committee within 24 hours.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Withdrawal criteria (after randomization): severe anesthetic or surgical complications (e.g., anaphylaxis, local anesthetic systemic toxicity, hemorrhagic shock); premature discontinuation of study drug due to adverse effects; actual surgical duration \< 90 minutes; postoperative mechanical ventilation > 24 hours; re-anesthesia, spinal anesthesia or reoperation during the study period; withdrawal of consent. Patients withdrawn after starting the infusion remain in the mITT analysis.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Dexmedetomidine 4 mcg/mL (200 mcg in 50 mL 0.9% saline). Loading dose 0.5 mcg/kg infused over 15 minutes starting 15 minutes before induction of general anesthesia, followed by a maintenance infusion of 0.5 mcg/kg/h throughout surgery until 2 hours after the end of surgery.
Drug: Dexmedetomidine
0.9% sodium chloride 50 mL in an identical syringe, infused at the same volume, rate and duration as the dexmedetomidine arm (15-minute loading infusion before induction, then maintenance until 2 hours after the end of surgery).
Drug: Placebo
Selective alpha-2 adrenergic agonist. Dexmedetomidine Invagen 200 mcg/2 mL (SIA Pharmidea, Latvia; Vietnamese marketing authorization 475114010723). Dose reduced to 0.3 mcg/kg/h for bradycardia with hypotension; stopped for HR \< 40/min, new 2nd-3rd degree AV block, refractory hypotension, or RASS \<= -3 / SpO2 \< 90% after extubation.
Also known as: Dexmedetomidine hydrochloride, Dexmedetomidine Invagen
Identical-appearing 0.9% sodium chloride solution administered with the same syringe, label, volume, rate and duration.
Also known as: 0.9% sodium chloride, normal saline
Incidence of postoperative delirium
Percentage of participants with at least one positive delirium assessment. Delirium is assessed with the 3-Minute Diagnostic Interview for Confusion Assessment Method-defined delirium (3D-CAM), or with the Confusion Assessment Method for the Intensive Care Unit (CAM-ICU) in patients who cannot be interviewed (Richmond Agitation-Sedation Scale \[RASS\] score -3 to -1; RASS range -5 \[unarousable\] to +4 \[combative\]). Both instruments give a dichotomous result (delirium present/absent). Assessments are performed three times daily (07:00-09:00, 12:00-14:00, 18:00-20:00) by blinded trained assessors.
Time frame: From the end of surgery through postoperative day 5 or hospital discharge, whichever comes first
Discrimination of the postoperative delirium nomograms (C-statistic)
Optimism-corrected C-statistic (area under the ROC curve; unitless, range 0.5-1.0, higher = better discrimination) of Model A (preoperative nomogram: age, MMSE, Clinical Frailty Scale, serum albumin, high-risk surgery, treatment group) and Model B (end-of-surgery nomogram: age, MMSE, Clinical Frailty Scale, surgical duration, cumulative time with MAP \< 65 mmHg, treatment group), internally validated with 1,000 bootstrap replicates. Reported separately for each model.
Time frame: From the end of surgery through postoperative day 5
Calibration slope of the postoperative delirium nomograms
Optimism-corrected calibration slope (unitless; ideal value 1; values below 1 indicate overfitting) of Model A and Model B, estimated by 1,000 bootstrap replicates. Reported separately for each model.
Time frame: From the end of surgery through postoperative day 5
Calibration-in-the-large of the postoperative delirium nomograms
Optimism-corrected calibration intercept (calibration-in-the-large; log-odds scale; ideal value 0) of Model A and Model B, estimated by 1,000 bootstrap replicates. Reported separately for each model.
Time frame: From the end of surgery through postoperative day 5
Brier score of the postoperative delirium nomograms
Optimism-corrected Brier score (mean squared difference between predicted probability and observed outcome; range 0-1, lower = better overall accuracy) of Model A and Model B, estimated by 1,000 bootstrap replicates. Reported separately for each model.
Time frame: From the end of surgery through postoperative day 5
Severity of postoperative delirium
Highest score on the 3D-CAM Severity scale (3D-CAM-S; range 0-7, higher scores mean more severe delirium; 0 none, 1 mild, 2 moderate, 3-7 severe) among all assessments.
Time frame: From the end of surgery through postoperative day 5
Time to onset of postoperative delirium
Hours from the end of surgery to the first positive delirium assessment; participants without delirium are censored at the last assessment.
Time frame: From the end of surgery through postoperative day 5
Duration of postoperative delirium
Days from the first positive delirium assessment until delirium is no longer diagnosed.
Time frame: From the end of surgery through postoperative day 5
Motor subtype of postoperative delirium
Number of participants with each motor subtype among those with delirium: hyperactive (RASS always \> 0), hypoactive (RASS always \<= 0) or mixed, based on RASS (range -5 to +4) at positive assessments.
Time frame: From the end of surgery through postoperative day 5
Incidence of bradycardia requiring treatment
Percentage of participants with heart rate \< 50 beats/min or a decrease \>= 20% from baseline requiring treatment.
Time frame: From the start of study-drug infusion to 2 hours after the end of surgery
Incidence of hypotension requiring treatment
Percentage of participants with mean arterial pressure \< 65 mmHg or a decrease \>= 20% from baseline requiring fluid or vasopressor.
Time frame: From the start of study-drug infusion to 2 hours after the end of surgery
Cumulative intraoperative hypotension time
Total minutes with mean arterial pressure \< 65 mmHg (non-invasive blood pressure measured every 3 minutes).
Time frame: From induction of anesthesia to the end of surgery
Study-drug dose reduction or discontinuation
Percentage of participants whose study-drug infusion was reduced or stopped because of adverse effects.
Time frame: From the start of study-drug infusion to 2 hours after the end of surgery
Time to extubation
Minutes from the end of surgery to tracheal extubation.
Time frame: Up to 24 hours after surgery
Length of stay in the post-anesthesia care unit
Minutes from admission to discharge from the post-anesthesia care unit.
Time frame: Up to 24 hours after surgery
Postoperative pain intensity
Pain score on the Visual Analog Scale (VAS; range 0-10 cm, 0 = no pain, 10 = worst imaginable pain; higher scores mean worse pain).
Time frame: 12, 24 and 48 hours after surgery
Postoperative opioid consumption
Cumulative opioid dose converted to intravenous morphine milligram equivalents.
Time frame: From induction of anesthesia to 48 hours after surgery
Major postoperative complications
Percentage of participants with complications of Clavien-Dindo grade III or higher (Clavien-Dindo classification, grades I-V; higher grades mean more severe complications).
Time frame: Until hospital discharge (up to 30 days after surgery)
Postoperative length of hospital stay
Days from surgery to hospital discharge.
Time frame: Until hospital discharge (up to 30 days after surgery)
In-hospital mortality
Percentage of participants who die from any cause during hospitalization.
Time frame: Until hospital discharge (up to 30 days after surgery)
Plasma interleukin-6 (IL-6) concentration
IL-6 concentration (pg/mL) in the laboratory substudy (first 60 participants, 30 per group).
Time frame: Before surgery (baseline), 2 hours and 24 hours after the end of surgery
Serum cortisol concentration
08:00 serum cortisol concentration (nmol/L) in the laboratory substudy (first 60 participants).
Time frame: 08:00 on the day of surgery before induction (baseline), 08:00 on postoperative day 1 and 08:00 on postoperative day 2
Serum C-reactive protein (CRP) concentration
CRP concentration (mg/L) in all participants.
Time frame: Before surgery (baseline), 24 hours and 48 hours after the end of surgery
Neutrophil-to-lymphocyte ratio (NLR)
Absolute neutrophil count divided by absolute lymphocyte count (unitless ratio) from complete blood count, in all participants.
Time frame: Before surgery (baseline), 24 hours and 48 hours after the end of surgery
Systemic immune-inflammation index (SII)
Platelet count x neutrophil count / lymphocyte count (x10\^9/L) from complete blood count, in all participants.
Time frame: Before surgery (baseline), 24 hours and 48 hours after the end of surgery
Area under the ROC curve of laboratory markers for postoperative delirium
Area under the receiver operating characteristic curve (AUC; unitless, range 0.5-1.0, higher = better discrimination, with DeLong 95% CI) of each marker (IL-6, cortisol, CRP, NLR, SII) for identifying postoperative delirium. Reported separately for each marker.
Time frame: Markers measured from baseline to 48 hours after surgery; delirium assessed from the end of surgery through postoperative day 5
Adjusted odds ratio of postoperative delirium associated with CRP, NLR and SII
Odds ratio (with 95% CI) for postoperative delirium per unit increase in each postoperative marker (CRP, NLR, SII), from multivariable logistic regression adjusted for age, MMSE, treatment group and high-risk surgery. Reported separately for each marker.
Time frame: Markers measured at 24 and 48 hours after surgery; delirium assessed from the end of surgery through postoperative day 5
Clinical net benefit of the postoperative delirium nomograms
Net benefit (unitless) by decision curve analysis across threshold probabilities of 5-40%, compared with treat-all and treat-none strategies, for Model A and Model B.
Time frame: From the end of surgery through postoperative day 5
Absolute risk difference in postoperative delirium by baseline-risk stratum
Difference in the percentage of participants with postoperative delirium (dexmedetomidine minus placebo, percentage points, with 95% CI) within each quartile of baseline delirium risk estimated by Model A (treatment set to placebo). The number needed to treat is derived as 1/absolute risk difference. Pre-specified exploratory analysis.
Time frame: From the end of surgery through postoperative day 5
Relative risk of postoperative delirium by baseline-risk stratum
Ratio of the risk of postoperative delirium (dexmedetomidine vs placebo, with 95% CI) within each quartile of baseline delirium risk estimated by Model A; heterogeneity explored by a baseline risk x treatment interaction term. Pre-specified exploratory analysis.
Time frame: From the end of surgery through postoperative day 5
Plan to share: Undecided — De-identified individual participant data underlying the published results, together with the statistical analysis code, may be shared upon reasonable request to the principal investigator after publication of the main results. A final decision will be made before study completion.
Start is estimated for Dec 2026; primary completion for Apr 2028, 16 months later.
Of 186 non-industry interventional studies with no phase under Emergence Delirium, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 36. This study's planned 16 months is below that.
Counting every sponsor, half of 186 studies reached it within 19 months; a quarter within 7 and three quarters within 36.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dexmedetomidine
Hanoi Medical University